Caption Management’s Aldeyra Therapeutics ALDX Stock Holding History

Caption Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$279K	Buy	165,000 +130,000	+371%	+$570K	﹤0.01%	1304
2025 Q4	$181K	Buy	+35,000	New	+$180K	﹤0.01%	1390
2025 Q3	–	Sell	-12,664	Closed	-$48.5K	–	1631
2025 Q2	$48.5K	Sell	12,664 -168,442	-93%	-$435K	﹤0.01%	1345
2025 Q1	$1.04M	Sell	181,106 -215,383	-54%	-$1.27M	0.01%	902
2024 Q4	$1.98M	Buy	+396,489	New	+$2.03M	0.02%	693
2022 Q1	–	Sell	-138,600	Closed	-$552K	–	1427
2021 Q4	$555K	Sell	138,600 -38,679	-22%	-$295K	0.01%	1225
2021 Q3	$1.56M	Buy	+177,279	New	+$1.63M	0.02%	867

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caption Management's ALDX Position: Q1 2026 in Review

Caption Management increased its Aldeyra Therapeutics (ALDX) stake by 371% in Q1 2026, buying an estimated $570K and bringing the position to 165,000 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Caption Management first reported a position in ALDX in Q3 2021 and has held it in 7 quarters since. The position peaked at $1.98M in Q4 2024. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Caption Management held 165,000 shares of Aldeyra Therapeutics worth $279K as of Q1 2026.
Caption Management bought 130,000 Aldeyra Therapeutics shares in Q1 2026, an estimated $570K.
Aldeyra Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1304 holding.
Caption Management first reported a position in Aldeyra Therapeutics in Q3 2021 and has held it in 7 quarters since.
Caption Management's Aldeyra Therapeutics position peaked at $1.98M in Q4 2024.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.